Drugs / REGN4336
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07594106 | Jul 2026 → Oct 2030 expected | castration-resistant prostate carcinoma, clear cell renal carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05125016 | Nov 2021 → Mar 2030 expected | castration-resistant prostate carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN4336 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07594106 ↗ |
| Modality | Monoclonal antibody | “REGN4336 (a PSMAxCD3 Bispecific Antibody)” NCT05125016 ↗ |